CRM1 inhibitors for treating epilepsy

The invention generally relates to the use of nuclear transport modulators, e.g., CRM1 inhibitors, of Formula (I) for treating epilepsy in a subject. Subjects can have unprovoked seizures without prior warning that affect one or both hemispheres of the brain. The disclosed methods can reduce the severity and occurrence of these unprovoked epileptic seizures and can result in resolution of epilepsy. The method comprises administering to the subject an effective amount of a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.